Issue Price
₹43
Per Share
GMP
NIL
Grey Market
Est. Listing
₹43
Expected Price
Min. Application
₹258,000
2 lots × 3000 shares
Goldline Pharmaceuticals is engaged in the business of marketing pharmaceutical products under the brand name “Goldline.” Its product range is divided into five segments:Goldline Pharma: This category includes 42 products to cater to specialties like Physicians, Orthopedics, ENT, Chest Physicians, General and Specialty Surgery, Gastroenterology, Neurology, and Urology.Goldline Cardinal: This category offers 54 products tailored for the Specialty division, serving medical fields such as Physicians, Diabetologists, Endocrinologists, Cardiologists, and General Physicians.Goldline Aayushman: This category comprises 18 products designed for the Specialty division, catering to medical fields such as Pediatricians, Child Specialists, Neonatologists, and General Practitioners.Goldline InLife: This category includes 22 products tailored for the Specialty division, serving Intensivists, Critical Care Consultants, Super Specialty Surgeons, and Physicians.Goldline Wellness: This category includes 10 products tailored Supportive care plays a crucial role in cancer therapy.The company do not manufacture products, it partner with third-party manufacturers who produce the medicines based on its market research and product specifications, ensuring quality and compliance with regulations.All products are marketed and sold under the Goldline brand through our network of distributors, who supply to retailers and wholesalers. The company currently works with 15 manufacturers and 7 distributors, and it also support hospitals and healthcare providers with procurement and material supply.The company sells products across the states of Maharashtra, Madhya Pradesh, Odisha, Jharkhand, Tamil Nadu, Rajasthan, and Bihar.Competitive Strengths:Experienced Promoters and Management Team with Industry Knowledge and a Track RecordAsset-light Business Model and Competitive ProductsScalable Business ModelWide and Diverse Range of Product OfferingsStrong Supplier and Vendor RelationshipsEstablished Distribution Network
Goldline Pharmaceutical Ltd. proposes to utilise the net proceeds from the Issue for the following objects:
| Category | Shares Offered | % Issue | Amount (₹ Cr)* | Subscription |
|---|---|---|---|---|
| Market Maker | 138,000 | — | ₹0.59 Cr | — |
| TOTAL | 138,000 | 100.00% | ₹0.59 Cr | — |
| Category | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 1 | 3,000 | ₹129,000 |
| Retail (Max) | 13 | 39,000 | ₹1,677,000 |
| sNII (Min) | 14 | 42,000 | ₹1,806,000 |
| bNII (Min) | 68 | 204,000 | ₹8,772,000 |
| Particulars | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|
| Revenue from Operations | 28.06 | 23.57 | 19.85 |
| EBITDA | 5.83 | 4.30 | 2.19 |
| Profit After Tax (PAT) | 2.83 | 1.81 | 0.26 |
| Net Worth | 10.35 | 7.87 | 5.89 |
| Total Assets | 26.28 | 22.93 | 19.39 |
| Reserves & Surplus | 1.65 | 3.76 | 2.08 |
| Total Borrowings | 11.03 | 11.13 | 10.83 |